AMRI to develop and manufacture parenteral generics for Genovi

By Dan Stanton

- Last updated on GMT

AMRI to develop and manufacture parenteral generics for Genovi
AMRI has won a contract to develop and manufacture five parenteral generic products for Genovi Pharmaceuticals.

The deal will see contract development and manufacturing organisation (CDMO) AMRI initially provide cGMP manufacture and analytical support for the registration of five of Genovi’s product candidates.

Last week AMRI shelled out $60m (€50m)​ for two Aptuit facilities – an aseptic manufacturing plant in Glasgow, UK, and an analytical chemistry services site in West Lafayette, Indiana – but spokesperson Gina Rothe said this announcement is unrelated to the acquisition.

“Although the two announcements are unrelated, we are excited about the ability to extend the benefits of our integrated service offering to new and existing customers for development, analytical services and commercial scale manufacturing of strategic and complex injectable products,”​ she told Outsourcing-Pharma.com.

Financial details were not disclosed, but AMRI will be reimbursed for technology transfer activities, analytical development and manufacture of regulatory submission batches, as well as receiving regulatory milestone payments. Under the terms of the deal, AMRI will supply Genovi with the products following regulatory approval.

Related news

Show more

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars